APPENDIX B

CHRONIC AND ACUTE TOXICITY CRITERIA COMPILED FOR COMPOUNDS NOT INCLUDED IN USEPA'S HHRAP

APPENDIX B

CHRONIC AND ACUTE HUMAN HEALTH TOXICITY CRITERIA COMPILED FOR COMPOUNDS NOT INCLUDED IN USEPA'S HHRAP

Human health toxicity criteria were used in the risk assessment to evaluate the potential for both long-term, chronic and short-term, acute health risks. The chronic toxicity criteria used in the risk assessment included oral cancer slope factors and inhalation unit risk factors for predicting excess lifetime cancer risks, and oral reference doses (RfDs) and inhalation reference concentrations (RfCs) for predicting the potential for long-term noncancer effects. The acute toxicity criteria consisted of acute reference air concentrations.

The toxicity criteria were compiled, where available, for each evaluated compound directly from the 2005 U.S. Environmental Protection Agency (USEPA) Human Health Risk Assessment Protocol (HHRAP) chemical-specific database. The information in this USEPA database is programmed into the IRAP software.¹ If toxicity criteria were not available from HHRAP, they were compiled using a hierarchy of toxicity data sources recommended by HHRAP.

This appendix presents the toxicity criteria that were compiled for compounds not already in USEPA's HHRAP database. Table 1 lists the chronic human health toxicity criteria compiled for this project, as well as the basis for each value. Table 2 lists the acute reference air concentrations compiled for this project, also including the basis for each value.

In addition, the oral cancer slope factors for two hexachlorodibenzodioxin congeners (1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD) were corrected from the values listed in HHRAP (and which were entered in the IRAP software exactly as indicated in HHRAP). HHRAP and IRAP include an oral cancer slope factor of 0.0062 (mg/kg-day)⁻¹ for these two PCDD/PCDF congeners, however, USEPA's Integrated Risk Information System (IRIS) lists the slope factor as 6,200 (mg/kg-day)⁻¹. The IRIS value was thus entered into IRAP.

Finally, three additional toxicity values were entered into the IRAP software for compounds discussed in HHRAP, but for which the HHRAP chemical-specific database lists "no data". A "no data" entry in HHRAP results in a "0" entry in the IRAP software. First, the USEPA-specified 2,3,7,8-TCDD oral cancer slope factor of $1.5E+5 (mg/kg-day)^{-1}$ was multiplied by the toxic equivalency factor (TEF) for each PCDD/PCDF congener (except the two HxCDDs noted above) and then this product was entered as the oral cancer slope factor into IRAP for each PCDD/PCDF congener. This enabled the IRAP program to calculate oral cancer risks for the mixture of PCDDs/PCDFs using the 2,3,7,8-TCDD slope factor in conjunction with 2,3,7,8-TCDD toxic equivalency factors. Second, an inhalation unit risk factor for 2,3,7,8-TCDD of 33 ($\mu g/m^3$)⁻¹ from USEPA's 1997 Health Effects Assessment Summary Tables was multiplied by the toxic equivalency factor (TEF) and then this product was entered for each PCDD/PCDF congener (except the two

¹ The IRAP software, which was programmed by Lakes Environmental to implement the 2005 HHRAP methodology, was used to perform the risk assessment calculations for stack and fugitive air emissions.

HxCDDs noted above which have their own IRIS-identified inhalation values of 1.3 $(\mu g/m^3)^{-1}$). Third, the oral cancer slope factor of 2 $(mg/kg-day)^{-1}$ for Aroclor 1254 identified in the HHRAP report but not in its chemical-specific database was entered into IRAP. Polychlorinated biphenyls (PCBs) were evaluated in the risk assessment as Aroclor 1254 based on an evaluation of the PCB homologue distribution measured during the Performance Demonstration Test in accordance with HHRAP guidance. Additionally, Aroclor 1254 was selected over Aroclor 1016 because it has more conservative toxicity criteria.

Table 1 Compilation of Chronic Human Health Toxicity Criteria for Compounds Not Included in USEPA's 2005 HHRAP (a)

| Toxicity Criteria | | | | | | Sources for Toxicity Criteria | | | | | | |
|-----------------------|--|-------------------------|--|--|--|---------------------------------------|--------------------|-------------------------|--|--|---|-----------------------|
| CAS # | Compound name | Oral RfD (mg/kg/day) | Oral cancer slope factor (mg/kg/day) ⁻¹ | Inhalation RfC (mg/m ³) | Inhalation unit risk factor (ug/m ³⁾⁻¹ | Health endpoint(s) | | Oral RfD (mg/kg/day) | Oral cancer slope factor (mg/kg/day) ⁻¹ | Inhalation RfC (mg/m ³) | Inhalation Unit risk factor (ug/m ³) [*] 1 | Health endpoint(s) |
| 563-58-6 | 1,1-Dichloropropene | NA | NA | NA | NA | NA |] [| | | | | |
| 95-63-6 | 1,2,4-Trimethylbenzene | NA | NA | NA | NA | NA | | | | | | |
| 142-28-9 | 1 3-Dichloropropage | | | | | Liver/ | | | | | | |
| 142 20 0 | r,o Dionioropropano | 0.02 | NA | 0.07 | NA | Kidney | | PPRTV | | RTR (b) | | PPRTV |
| 108-60-1 | 2,2'-oxybis (1-Chloropropane) | 0.04 | NA | 0.14 | NA | Blood | | IRIS | | RTR (b) | | IRIS |
| 594-20-7 | 2,2-Dichloropropane | NA | NA | NA | NA | NA | | | | | | |
| 625-86-5 | 2,5-Dimethylfuran | NA | NA | NA | NA | NA | | | | | | |
| 2216-30-0 | 2,5-Dimethylheptane | NA | NA | NA | NA | NA | 4 | | | - | | |
| 17559-81-8 | 2,5-Dione, 3-hexene | NA | NA | NA | NA | NA | | | | | | |
| 78-93-3 | 2-Butanone | 0.6 | NA | 5 | NA | Developmental/ Reproductive System | | IRIS | | IRIS | | IRIS |
| 95-49-8 | 2-Chlorotoluene | 0.02 | NA | 0.07 | NA | Body Weight | 11 | IRIS | | RTR (b) | | IRIS |
| 591-78-6 | 2-Hexanone | NA | NA | NA | NA | NA |] [| | | | | |
| 3221-61-2 | 2-Methyl octane | NA | NA | NA | NA | NA | | | | | | |
| 91-57-6 | 2-Methylnaphthalene | 0.004 | NA | 0.014 | NA | Respiratory tract | | IRIS | | RTR (b) | | IRIS |
| 34246-54-3 | 3-Ethyl benzaldehyde | NA | NA | NA | NA | NA | | | | | | |
| 763-93-9 | 3-Hexen-2-one | NA | NA | NA | NA | NA | - | | | - | | |
| 625-33-2 | 3-Penten-2-one (ethylidene acetone) | NA | NA | NA | NA | NA | | | | | | |
| 141-79-7 | 3-Penten-2-one, 4-methyl | NA | NA | NA | NA | NA | | | | | | |
| 534-52-1 | 4,6-Dinitro-2-methylphenol | 0.004 | NA | 0.014 | NA | Nervous System | - | ATSDR | | RTR (b) | | ASTDR |
| 106-43-4 | 4-Chlorotoluene | 0.07 | NA | 0.245 | NA | Liver/ Kidney | | PPRTV | | RTR (b) | | PPRTV |
| 4748-78-1 | 4-Ethyl benzaldehyde | NA | NA | NA | NA | NA | - | | | | | |
| 301-02-0 | 9-Octadecenamide (oleamide) | NA | NA | NA | NA | NA | | | | | | |
| 7429-90-5 | Aluminum | 1 | NA | 0.005 | NA | Developmental/ | | | | | | |
| 92-87-5 | Benzidine | 0.003 | 230 | NA | 0.067 | Urinary/ Nervous System/ Liver | | IRIS | IRIS | FFRIV | IRIS | IRIS |
| 192-97-2 | Benzo(e)pyrene | NA | NA | NA | NA | NA | 11 | | | | | |
| 191-24-2 | Benzo(g,h,i)perylene | NA | NA | NA | NA | NA |] [| | | | | |
| 93-58-3 | Benzoic acid, methyl ester (methyl benzoate) | NA | NA | NA | NA | NA | | | | | | |
| 111-91-1 | Bis(2-chloroethoxy) methane | 0.003 | NA | 0.0105 | NA | Liver | 11 | PPRTV | | RTR (b) | | PPRTV |
| 108-86-1 | Bromobenzene | NA | NA | NA | NA | NA |] [| | | | | |
| 74-97-5 | Bromochloromethane | NA | NA | NA | NA | NA | | | | | | |
| 104-51-8 | Butylbenzene, n- | NA | NA | NA | NA | NA | | | | | | |
| 135-98-8 | Butylbenzene, sec | NA | NA | NA | NA | NA | 4 | | | | | |
| 98-06-6 | Butylbenzene, tert | NA | NA | NA | NA | NA | - | | | | | |
| 7440-48-4 | Carbazole | INA | NA | NA . | INA | Respiratory tract/ | | | | | | |
| 7440 50 5 | | 0.01 | NA | 0.0001 | NA | Blood | 4 | AISDR | | ASTDR | | AISDR |
| 7440-50-8 | Diallata | 0.01 | NA | 0.035 | NA | Gastrointestinal | ┥┝ | AISDR | | KIK (b) | | AISDR |
| 2303-16-4 132-64-0 | Dianale | 0.001 | NA NA | INA 0.0035 | NA NA | NA Organ (weight) | $\left\{ \right\}$ | PPRT\/ | | RTP (b) | <u> </u> | PPRT\/ |
| 102-04-9 | | 0.001 | 11/2 | 0.0030 | 11/2 | Body Weight/ | | 111111 | | | | 111111 |
| 122-39-4 | Dipnenylamine | 0.025 | NA | 0.0875 | NA | Kidney/ Liver | | IRIS | | RTR (b) | | IRIS |

Table 1 Compilation of Chronic Human Health Toxicity Criteria for Compounds Not Included in USEPA's 2005 HHRAP (a)

| Toxicity Cri | teria | | | | | | 1 [| Sources for T | oxicity Criteria | 1 | | |
|---|--|-------------|-----------------------------|--------------------------|-----------------------------------|--|-----|---------------|-----------------------------|----------------------|---|---------------|
| CAS # | | Oral RfD | Oral cancer slope factor | Inhalation | Inhalation unit risk factor | | | Oral RfD | Oral cancer slope factor | Inhalation RfC | Inhalation Unit risk factor (ug/m ³) | Health |
| CAS # | | (mg/kg/day) | (mg/kg/day) | RTC (mg/m ⁻) | (ug/m [*]) | Health endpoint(s) | | (mg/kg/day) | (mg/kg/day) | (mg/m ⁺) | | enapoint(s) |
| 1031-07-8 | Endosultan sultate | NA | NA | NA | NA | NA | | | | | | |
| 7421-93-4 | Endrin aldenyde | NA | NA | NA | NA | NA | | | | | | |
| 53494-70-5 | Endrin ketone | NA | NA | NA | NA | NA | | | | | | |
| 76-13-1 | Freon 113 (1,1,2-trichloro-1,2,2- trifluoroethane) | 3 | NA | 10.5 | NA | Nervous System | | IRIS | | RTR (b) | | IRIS |
| 74-88-4 | lodomethane | NA | NA | NA | NA | NA | 1 [| | | | | |
| 99-87-6 | Isopropyl toluene, p- | NA | NA | NA | NA | NA | 1 [| | | | | |
| 7439-96-5 | Manganese | 0.14 | NA | 0.00005 | NA | Nervous System | 1 [| IRIS | | IRIS | | IRIS |
| 62-75-9 | N-nitrosodimethylamine | NA | 51 | NA | 0.014 | Liver | 1 [| | IRIS | | IRIS | IRIS |
| 198-55-0 | Perylene | NA | NA | NA | NA | NA | 1 [| | | | | |
| 2240-47-3 | Phosphine imide, P,P,P-triphenyl | NA | NA | NA | NA | NA | 1 [| | | | | |
| 103-65-1 | Propylbenzene, n- | NA | NA | NA | NA | NA | 1 [| | | | | |
| 7440-62-2 | Vanadium | 0.003 | NA | 0.0002 | NA | Respiratory tract/ Kidney | | ATSDR | | ATSDR | | ATSDR |
| 58-89-9 | γ-BHC (Lindane) | 0.0047 | NA | NA | NA | Liver/blood | | OPPTS HED (c) | OPPTS HED (c) | | OPPTS HED (c) | OPPTS HED (c) |
| 319-86-8 | δ-BHC | 0.083 | NA | NA | NA | Liver | | CPF (d) | | | | CPF (d) |
| 110-54-3 | 1-Hexane (n-hexane) | 0.06 | NA | 0.7 | NA | Nervous System | | HEAST | | IRIS | | IRIS/HEAST |
| 79-10-7 | Acrylic Acid | 0.5 | NA | 0.001 | NA | Developmental/ Respiratory Tract | | IRIS | | IRIS | | IRIS |
| 107-21-1 | Ethylene Glycol | 2 | NA | 1.3 | NA | Kidney | | IRIS | | ATSDR | | IRIS |
| 80-62-6 | Methyl methacrylate | 1.4 | NA | 0.7 | NA | Organ(weight)/ Respiratory Tract | | IRIS | | IRIS | | IRIS |
| 1634-04-4 | methyl tert-butyl ether | 0.3 | NA | 3 | NA | Liver/Kidney | | ATSDR | | IRIS | | IRIS |
| 75-56-9 | Propylene oxide | NA | 0.24 | 0.03 | 0.0000037 | Gastrointestinal/ Respiratory Tract | | | IRIS | IRIS | IRIS | IRIS |
| 33213-65-9 | Endosulfan II | NA | NA | NA | NA | NA | | | | | | |
| 7446-09-5 | Sulfur dioxide | NA | NA | 0.078 | NA | Respiratory Tract | | | | NAAQS (e) | | |
| 10102-44-0 | Nitrogen oxides | NA | NA | 0.1 | NA | Respiratory Tract | | | | NAAQS (e) | | |
| Additional Compounds Addressed in Fugitive Air Emissions Inhalation Risk Assessment | | | | | | | | | | | | |
| 106-99-0 | 1,3-Butadiene | | | 2.00E-03 | 3.00E-05 | | | | | IRIS | IRIS | |
| 110-82-7 | Cyclohexane | | | 6 | NA | | | | | IRIS | | |

NA = not available

-- = not applicable. Only the inhalation pathway of exposure was evaluated.

(a) Heirarchy for chronic toxicity data, based on 2005 HHRAP: 1) EPA's Integrated Risk Information System (IRIS); 2) EPA's provisional peer-reviewed toxicity values (PPRTV); 3) Other - a) CALEPA (California Environmental Protection Agency) chronic reference exposure level (REL) and unit risk factor (URF); b) Agency for Toxic Substances and Disease Registry (ATSDR) chronic minimum risk level (MRL); c) USEPA's 1997 Health Effects Assessment Summary Tables (HEAST).

(b) RTR = route to route extrapolation, based on Appendix A-2 of USEPA's 2005 HHRAP. RTR was conducted if an oral toxicity value was available but no inhalation toxicity value was available. Inhal RfC (mg/m3) = Oral RfD (mg/kg-day) * 70 kg BW / 20 m3/day. This assumes that the toxicity of the compound is equivalent when inhaled or ingested; this is used as an initial screening tool.

(c) OPPTS HED = USEPA's Office of Prevention, Pesticides and Toxic Substances, Health Effects Division. 2002. Revised HED Risk Assessment for Lindane. DP Barcode D280622. Reregistration case #0315. January 30, 2002.

(d) CPF = CPF Associates, Inc. 2006. Comments on Assessment of Lindane and Other Hexachlorocyclohexane Isomers. EPA-HQ-OPP-2006-0034. www.cpfassociates.com/pdf/HCH_Assessment_Comments_2006.pdf.

(e) NAAQS = National Ambient Air Quality Standard set under the U.S. Clean Air Act

Table 2

Compilation of Acute Inhalation Toxicity Criteria for Compounds Not Included in USEPA'S 2005 HHRAP

| | | Тох | cicity Criter | Acute Inhalation | | |
|------------|---|---------------------------------------|--------------------------------|--------------------------------|---|--|
| CAS Number | Compound | AEGL-1 (mg/m ³) (b) | ERPG-1 (mg/m ³) | TEEL-1 (mg/m ³) | CALEPA Acute REL (mg/m ³) | Reference Air Concentration Used in Risk Assessment (mg/m ³) |
| 563-58-6 | 1 1-Dichloropropene | | | 12.5 | | 12.5 |
| 95-63-6 | 1 2 4-Trimethylbenzene | 687 | | 150 | | 687 |
| 142-28-9 | 1 3-Dichloropropage | 007 | | 75 | | 75 |
| 108-60-1 | 2 2'-oxybis (1-Chloropropane) | | | 75 | | 75 |
| 594-20-7 | 2.2-Dichloropropage | | | 60 | | 60 |
| 625-86-5 | 2.5-Dimotopiopane | | | 00 | | NA |
| 2216-30-0 | 2.5-Dimethylhentane | | | 350 (d) | | 350 |
| 17550-81-8 | | | | 330 (u) | | 550 NA |
| 78.02.2 | 2-Butanono (MEK) | 590 | | | 12 | 12 |
| 05-40-8 | 2-Chlorotoluono | 569 | | 400 | 13 | 10 |
| 501 79 6 | | | | 400 | | 400 |
| 391-78-0 | 2-Rexample | | | 40 | | 40 |
| 3221-01-2 | 2-Methyl octane | | | 20 | | NA 20 |
| 91-57-6 | 2-Methylnaphthalene | | | 20 | | 20 |
| 34246-54-3 | 3-Ethyl benzaldenyde | | | 150 (C) | | 150 |
| 763-93-9 | 3-Hexen-2-one | | | | | NA |
| 625-33-2 | 3-Penten-2-one (ethylidene acetone) | | | | | NA |
| 141-79-7 | 3-Penten-2-one, 4-methyl (mesityl oxide) | | | 100 | | 100 |
| 534-52-1 | 4,6-Dinitro-2-methylphenol (4,6-dinitro- o-cresol) | | | 0.2 | | 0.2 |
| 106-43-4 | 4-Chlorotoluene | | | 350 | | 350 |
| 4748-78-1 | 4-Ethyl benzaldehyde | | | 150 (c) | | 150 |
| 301-02-0 | 9-Octadecenamide (oleamide) | | | | | NA |
| 208-96-8 | Acenaphthylene | | | 0.2 | | 0.2 |
| 7429-90-5 | Aluminum | | | 30 | | 30 |
| 92-87-5 | Benzidine | | | 0.5 | | 0.5 |
| 192-97-2 | Benzo(e)pyrene | | | | | NA |
| 191-24-2 | Benzo(g,h,i)perylene | | | 30 | | 30 |
| 93-58-3 | Benzoic acid, methyl ester (methyl benzoate) | | | | | NA |
| 111-91-1 | Bis(2-chloroethoxy) methane | | | 15 | | 15 |
| 108-86-1 | Bromobenzene | | | 15 | | 15 |
| 74-97-5 | Bromochloromethane | | | 3000 | | 3000 |
| 104-51-8 | Butylbenzene, n- | | | 125 | | 125 |
| 135-98-8 | Butylbenzene, sec | | | 25 | | 25 |
| 98-06-6 | Butylbenzene, tert | | | 125 | | 125 |
| 86-74-8 | Carbazole | | | 2.5 | | 2.5 |
| 7440-48-4 | Cobalt | | | 3 | | 3 |
| 7440-50-8 | Copper | | | | 0.1 | 0.1 |
| 2303-16-4 | Diallate | | | | | NA |
| 132-64-9 | Dibenzofuran | | | 30 | | 30 |
| 122-39-4 | Diphenylamine | | | 30 | | 30 |
| 1031-07-8 | Endosulfan sulfate | | | | | NA |
| 7421-93-4 | Endrin aldehyde | | | | | NA |
| 53494-70-5 | Endrin ketone | | | | | NA |
| 76-13-1 | Freon 113 (1,1,2-trichloro-1,2,2-trifluoroethane) | | | 10000 | | 10000 |
| 74-88-4 | Iodomethane (methyl iodide) | | 145 | | | 145 |
| 99-87-6 | Isopropyl toluene, p- | | | | | NA |
| 7439-96-5 | Manganese | | | 3 | | 3 |
| 62-75-9 | N-nitrosodimethylamine | | | 10 | | 10 |
| 198-55-0 | Perylene | | | | | NA |

Table 2

Compilation of Acute Inhalation Toxicity Criteria for Compounds Not Included in USEPA'S 2005 HHRAP

| | | Тох | cicity Criter | Acute Inhalation | | | | | |
|---|----------------------------------|---------------------------------------|-------------------|--------------------------------|---|--|--|--|--|
| CAS Number | Compound | AEGL-1 (mg/m ³) (b) | ERPG-1 (mg/m³) | TEEL-1 (mg/m ³) | CALEPA Acute REL (mg/m ³) | Reference Air Concentration Used in Risk Assessment (mg/m ³) | | | |
| 2240-47-3 | Phosphine imide, P,P,P-triphenyl | | | | | NA | | | |
| 103-65-1 | Propylbenzene, n- (isocumene) | | | 400 | | 400 | | | |
| 7440-62-2 | Vanadium | | | 0.15 | | 0.15 | | | |
| 58-89-9 | γ-BHC (Lindane) | | | 1.5 | | 1.5 | | | |
| 319-86-8 | δ-BHC | | | | | NA | | | |
| 110-54-3 | 1-Hexane (n-hexane) | | | 1,500 | | 1,500 | | | |
| 79-10-7 | Acrylic Acid | 4.4 | 5.9 | | 6 | 6.0 | | | |
| 107-21-1 | Ethylene Glycol | | | 100 | | 100 | | | |
| 80-62-6 | Methyl methacrylate | 70 | | | | 70 | | | |
| 1634-04-4 | methyl tert-butyl ether | 180 | | | | 180 | | | |
| 75-56-9 | Propylene oxide | 173 | | | 3.1 | 3.1 | | | |
| 7446-09-5 | Sulfur dioxide | | | | 0.66 | 0.66 | | | |
| 10102-44-0 | Nitrogen dioxide | | | | 0.47 | 0.47 | | | |
| 33213-65-9 | Endosulfan II | | | | | NA | | | |
| Additional Compounds Addressed in Fugitive Air Emissions Inhalation Risk Assessment | | | | | | | | | |
| 106-99-0 | 1,3-Butadiene | 1,480 | | | | 1,480 | | | |
| 110-82-7 | Cyclohexane | | | 1,000 | | 1,000 | | | |

Abbreviations:

HHRAP = USEPA's 2005 Human Health Risk Assessment Protocol for Hazardous Waste Combustion Facilities.

NA = Acute inhalation values were not available from the referenced data sources.

(a) Hierarchy for acute inhalation toxicity criteria, based on 2005 HHRAP: 1) CALEPA RELs, 2) USEPA AEGL-1, 3) ERPG-1, and 4) TEEL-1. Definitions are provided below:

CALEPA REL = California Environmental Protection Agency Acute Reference Exposure Level. The acute REL is the concentration level at or below which no adverse health effects are anticipated for a 1-hour exposure duration.

USEPA AEGL-1 = Acute exposure guideline level developed by USEPA. The AEGL-1 is the 1-hour average concentration in air below which mild transient effects (e.g., irritation) are not expected to occur in the general population, including susceptible individuals, but above which such transient effects might occur. AEGLs are developed to evaluate intermittent, short-term exposures.

ERPG-1: The maximum airborne concentration below which it is believed that nearly all individuals could be exposed for up to one hour without experiencing other than mild transient adverse health effects or perceiving a clearly defined, objectionable odor.

TEEL-1: The maximum airborne concentration below which it is believed that nearly all individuals could be exposed without experiencing other than mild transient adverse health effects or perceiving a clearly defined, objectionable odor.

(b) All listed AEGLs are interim values except for methyl tert butyl ether and 1,2,4-trimethylbenzene which are proposed AEGLs.

- (c) TEEL-1 is for 2-ethyl benzaldehyde, no value was available for 3- or 4-ethyl benzaldehyde.
- (d) TEEL-1 is for 2,2-dimethylheptane, no value was available for 2,5-dimethylheptane.